Comparing antibody and small-molecule therapies for cancer

被引：623

作者：

Imai, Kohzoh

Takaoka, Akinori

机构：

[1] Sapporo Med Univ, Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[2] Univ Tokyo, Fac Med, Grad Sch Med, Dept Immunol,Bunkyo Ku, Tokyo 1130033, Japan

来源：

NATURE REVIEWS CANCER | 2006年 / 6卷 / 09期

关键词：

D O I：

10.1038/nrc1913

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-molecule compounds have been approved for cancer treatment. Both antibodies and small-molecule compounds are therefore promising tools for target-protein-based cancer therapy. We discuss and compare the distinctive properties of these two therapeutic strategies so as to provide a better view for the development of new drugs and the future direction of cancer therapy.

引用

页码：714 / 727

页数：14

共 163 条

[51] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[52]

GEYER CE, 2006, SCI SPECIAL SESSION

[53] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Scagliotti, G ;

Rosell, R ;

Miller, V ;

Natale, RB ;

Schiller, JH ;

von Pawel, J ;

Pluzanska, A ;

Gatzemeier, M ;

Grous, J ;

Ochs, JS ;

Averbuch, SD ;

Wolf, MK ;

Rennie, P ;

Fandi, A ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784

[54] Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer [J].

Gibson, Tara Beers ;

Ranganathan, Aarati ;

Grothey, Axel .

CLINICAL COLORECTAL CANCER, 2006, 6 (01) :29-31

[55]

*GLAX, 2005, GLAX REC POS DAT HAL

[56] Immune evasion of tumor cells using membrane-bound complement regulatory proteins [J].

Gorter, A ;

Meri, S .

IMMUNOLOGY TODAY, 1999, 20 (12) :576-582

[57]

GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13

[58]

HALE G, 1985, J IMMUNOL, V134, P3056

[59] Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib [J].

Han, SW ;

Kim, TY ;

Hwang, PG ;

Jeong, S ;

Kim, J ;

Choi, IS ;

Oh, DY ;

Kim, LH ;

Kim, DW ;

Chung, DH ;

Im, SA ;

Kim, YT ;

Lee, JS ;

Heo, DS ;

Bang, YJ ;

Kim, NK .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2493-2501

[60] The hallmarks of cancer [J].

Hanahan, D ;

Weinberg, RA .

CELL, 2000, 100 (01) :57-70

← 1 2 3 4 5 6 7 8 9 10 →